Warsaw

• A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejec … Ended
  2023-508736-62-00 4 2024-08-08 Heart failure (HF) with reduced ejection fraction (HFrEF)
• A Phase 2 Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejecti … Ended
  2023-508737-13-00 4 2024-08-08 chronic heart failure
• Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat … Ended
  2023-508170-28-00 4 2024-08-07 alcohol-related liver disease
• A study on the immune response, safety and the occurrence of RSV-associated respiratory tract illness after administration of RSV OA vaccine … Ended
  2023-509455-13-00 11 2024-08-05 Respiratory Syncytial Virus Infections
• Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended
  2023-508679-34-00 4 2024-07-30 Ulcerative Colitis
• A trial to learn how well balcinrenone in combination with dapagliflozin works and how safe it is compared to dapagliflozin alone in adults … Ended
  2023-509709-63-00 4 2024-07-30 Chronic Kidney Disease and Albuminuria
• A research study comparing how well different doses of the medicine NNC0487-0111 lower blood sugar in people with type 2 diabetes Ended
  2023-509412-28-00 4 2024-07-26 Type 2 Diabetes
• REIMAGINE 1: A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in people with type 2 diabete … Ended
  2022-502677-42-00 5 2024-07-24 Type 2 diabetes
• A Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer Ended
  2022-502982-49-00 4 2024-07-15 Metastatic Castration-Resistant Prostate Cancer
• A study to evaluate the efficacy and safety of gliclazide MR in patients with type 2 diabetes inadequately controlled with dapagliflozin wit … Ended
  2024-511408-18-00 5 2024-07-15 Type 2 Diabetes inadequately controlled with dapagliflozin with or wit
• “A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis” Ended
  2023-503289-22-00 4 2024-07-05 Relapsing Multiple Sclerosis
• A Phase IIb Two-Cohort, Randomised, Placebo controlled, Double blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Ch … Ended
  2023-510148-19-00 4 2024-07-03 Chronic Heart Failure
• A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa … Ended
  2023-508377-82-00 10 2024-06-27 Hidradenitis Suppurativa (HS)
• A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced l … Ended
  2023-509644-10-00 9 2024-06-27 Advanced Non-small Cell Lung Cancer
• A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokine … Ended
  2022-502963-39-00 7 2024-06-20 Glycogen storage disease type 1a (GSD1a)
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer
• Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended
  2023-505712-37-00 10 2024-06-06 The participants must have a histologically confirmed diagnosis of res
• Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic … Ended
  2022-503009-39-00 3 2024-06-04 Subacute Cutaneous Lupus Erythematosus
• AMX0035 and Progressive Supranuclear Palsy Ended
  2023-505893-14-00 5 2024-06-04 Progressive Supranuclear Palsy
• A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on subjects with Ataxia-Te … Ended
  2023-509077-23-00 5 2024-06-03 Ataxia Telangiectasia
• Phase 2 study comparing SAR447537 to plasma-derived A1PI therapy for AATD emphysema Ended
  2023-508084-76-00 4 2024-05-31 Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
• A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap … Ended
  2022-502653-34-01 11 2024-05-30 Atopic dermatitis and moderate-to severe atopic hand eczema
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2022-501196-41-00 5 2024-05-29 Dermatitis atopic
• A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Ended
  2022-502481-24-00 4 2024-05-23 Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

Showing 1,345–1,368 of 1,708 trials